State of New Jersey Common Pension Fund D purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,341,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its position in shares of Regeneron Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after purchasing an additional 416,192 shares during the last quarter. BlackRock Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.7% during the 2nd quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock valued at $3,039,305,000 after purchasing an additional 41,406 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.9% during the 2nd quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock valued at $2,588,533,000 after purchasing an additional 148,962 shares during the last quarter. Artisan Partners Limited Partnership increased its position in shares of Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock valued at $963,852,000 after purchasing an additional 29,252 shares during the last quarter. Finally, Polen Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 7.3% during the 2nd quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock valued at $779,105,000 after purchasing an additional 108,413 shares during the last quarter. 67.57% of the stock is owned by hedge funds and other institutional investors.

WARNING: “3,000 Shares in Regeneron Pharmaceuticals, Inc. (REGN) Acquired by State of New Jersey Common Pension Fund D” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/3000-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-state-of-new-jersey-common-pension-fund-d/1677723.html.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $408.41 on Friday. The stock has a market capitalization of $42.59 billion, a PE ratio of 37.35, a price-to-earnings-growth ratio of 1.37 and a beta of 1.56. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.75 and a quick ratio of 3.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the previous year, the business posted $2.82 EPS. The company’s quarterly revenue was up 21.2% on a year-over-year basis. equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.77 EPS for the current fiscal year.

Several equities research analysts have recently commented on the stock. Robert W. Baird raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research report on Friday. BMO Capital Markets set a $491.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $472.00 price target (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and set a $471.00 price target (up previously from $418.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Finally, Leerink Swann reissued an “outperform” rating and issued a $580.00 target price (up from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $488.57.

In related news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Robert E. Landry sold 526 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the transaction, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,296,456.81. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,468 shares of company stock worth $42,312,448. Company insiders own 10.80% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.